Ardana announces Board Change

Edinburgh, UK: 8 October 2007: Ardana plc (LSE:ARA) today announces that the Company’s Chief Executive Officer, Dr. Maureen Lindsay, has informed the Board that, after nearly 7 years of service, she wishes to step down from her position as CEO and a Director of the Company. Dr. Huw Jones, a non-executive Director of the Company since June 2006, has been appointed as Ardana’s new CEO with immediate effect. Dr. Lindsay will remain with the Company until the end of 2007 to assist with the transition.

Huw Jones, 47, has a strong background in senior management in the pharmaceutical industry, most recently at CV Therapeutics Inc., a NASDAQ listed pharmaceutical company where he was President, Europe. He also fulfilled a number of senior roles at Elan Pharmaceuticals and SmithKlineBeecham between 1986 and 2002. In 2002 he co-founded Daffodil Consulting LLP, providing strategic advice to biopharmaceutical companies. He became non-executive Chairman of Ashbourne Pharmaceuticals Ltd in 2002, a position he retained until its sale to Sinclair Pharma plc in 2006. He holds a PhD in Pharmacology from the University of Birmingham.

Dr. Maureen Lindsay joined Ardana in January 2001 as Chief Operating Officer and has been CEO since March 2004, leading the Company’s successful flotation on the main market of the London Stock Exchange in March 2005. During the period of her leadership the Company has built a strong product pipeline focused on reproductive health which now includes three marketed products, two products in Phase III, two products in Phase II for three indications and several follow-on products in Phase I.

Dr. Simon Best, non-executive Chairman of Ardana, said:

"The Board wishes to place on record its gratitude to Maureen Lindsay for her achievements as CEO of Ardana. She has created one of the strongest product pipelines in the UK biotech industry, with good progress being made across the portfolio.  We wish her every success with her future plans.

“We are delighted that Huw Jones has agreed to become the Company’s new CEO. We are approaching the time when we need to consider the commercialisation of a number of products in our portfolio, in addition to our lead product Teverelix LA, a process in which his wealth of experience in the pharmaceutical industry and business development skills will be of great value.

“Our licensing activities on Teverelix LA are progressing well with several potential partners at different stages of discussion.  In addition, following the recent publication of the positive Phase II data on prostate cancer the discussions have broadened with approaches from other new parties interested in the opportunity.”

Dr. Maureen Lindsay added:

“I have thoroughly enjoyed my time at Ardana and wish the Company and all of its employees every success in the future. We have worked hard to build a broad and valuable pipeline at Ardana and I am confident that its global commercial potential, particularly of Teverelix LA, will be realised.”

As previously announced, Ardana will be releasing its interim results for the six months ended 30 September 2007 on Tuesday 9 October 2007.

For more information contact:

back to top